Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report

[1]  Alok V. Joglekar,et al.  Personalized T cell-mediated cancer immunotherapy: progress and challenges. , 2017, Current opinion in biotechnology.

[2]  H. Mochizuki,et al.  A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis , 2017, Case reports in medicine.

[3]  O. Nanni,et al.  Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience , 2017, Melanoma research.

[4]  A. Chhabra,et al.  Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53 , 2017, Expert opinion on therapeutic targets.

[5]  N. Agarwal,et al.  Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma , 2016, Cancer Immunology, Immunotherapy.

[6]  P. Sharma,et al.  Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody , 2016, Journal of Immunotherapy for Cancer.

[7]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[8]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[9]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[11]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[13]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[14]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[15]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[16]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[17]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[18]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[19]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[20]  J. Kirkwood,et al.  Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[22]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  U. Reinhold,et al.  Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma , 1997, The Lancet.

[24]  D. Longo,et al.  Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma , 1995, Cancer.

[25]  A. Buzaid,et al.  Acute rhabdomyolysis after concurrent administration of interleukin‐2, interferon‐alfa, and chemotherapy for metastatic melanoma , 1995, Cancer.

[26]  R. P. Thompson,et al.  Drug Points: Rhabdomyolysis after treatment with interferon alfa , 1994, BMJ.

[27]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.